When Marianne De Backer took over Vir Biotechnology in 2023, the San Francisco company did not get a gentle makeover. It got a drastic trim. Programs were cut, lab space was consolidated and capital was steered hard toward hepatitis and oncology. All of it followed a very public clinical flop that forced Vir to confront where it could realistically compete. What is left is a smaller, tightly focused biotech that has tried to turn a failed program into licensing cash and partnerships with bigger drugmakers.
Topline flop forced an overhaul
In July 2023, Vir revealed that its Phase 2 PENINSULA trial of VIR-2482 did not meet its primary or secondary efficacy endpoints, a result the company described as disappointing. According to Vir Biotechnology, the miss knocked out the commercial rationale for the program and pushed leadership to speed up a strategic reset. That failure became the immediate catalyst for a wave of program cuts and a broader reconsideration of Vir’s research footprint.
Big cuts and closed labs
By December 2023, Vir had moved from rethinking to cutting. A restructuring eliminated about 75 jobs and included plans to close R&D sites in Missouri and Oregon, according to BioPharma Dive. Local reporting later chronicled the Bay Area fallout, with one outlet noting the company pared roughly a quarter of its Bay Area staff in 2024 as sites were shuttered or absorbed. Those operational moves set the financial and organizational table for the licensing and collaboration deals that came next.
Licensing deals and a retooled pipeline
Management’s response was to turn pipeline assets into cash and to share development risk. Corporate disclosures show Vir booked license and reimbursement revenue that helped blunt R&D costs, while it in-licensed and licensed out multiple programs as part of a pivot toward oncology and hepatitis. Company filings cite a $64.3 million initial reimbursement tied to a December 2025 Norgine license and show that an earlier Sanofi transaction materially offset prior R&D spending. These arrangements, along with a strategic collaboration to advance a masked T-cell engager program, reshaped Vir’s pipeline and extended its near-term financial runway, according to filings with the SEC and an investor update.
De Backer the dealmaker
Much of that shift is attributed to De Backer, who left Bayer to become Vir’s CEO in 2023 and, by many accounts, pushed the company to sacrifice breadth in favor of commercial partnerships. A recent profile in The Business Journals notes that she closed sites and signed licensing agreements that together generated hundreds of millions of dollars in value. Industry coverage at the time of her hire highlighted her dealmaking record at Bayer, a skillset Vir leaned on as it reset its strategy.
Where Vir stands now
Vir’s latest proxy filing shows how far the reset has gone. Headcount dropped from 587 employees at the end of 2023 to about 408 by the end of 2024, a reduction the company frames as part of a strategic reorganization aimed at higher-value programs. The same filing describes substantial savings in R&D and SG&A, which management says have been redirected into prioritized hepatitis and oncology work. The result is a much smaller workforce and a portfolio that mixes internal programs with those advanced alongside partners.
What to watch next
All of this now has to translate into data. Investors and patients are watching for clinical readouts and progress with collaborators. Updated Phase 1 results for the PSMA-targeted PRO-XTEN TCE VIR-5500 were shared with partners and scheduled for presentation at ASCO GU, and Vir has announced a global strategic collaboration to move that program forward. The company investor materials report year-end cash in the high hundreds of millions and state that licensing and collaboration proceeds are expected to extend the cash runway into late 2027 to 2028 as trials progress. The key question is whether the pivot from a failed flu antibody to a partnership-heavy oncology and hepatitis strategy ultimately delivers on that bet.
